CJC-1295 / Ipamorelin Blend

This blend pairs two peptides that both nudge the pituitary to release growth hormone — one longer-acting, one shorter and more selective.

It's studied in performance and recovery research — how combining two growth-hormone signals affects the size and pattern of hormone pulses.

Animal studies showed combined release greater than either alone. Human performance claims are unproven.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

Both compounds are investigational. Neither is FDA-approved for human therapeutic or performance use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Water retention and insulin-sensitivity changes in high-dose animal models.

• Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295. J Clin Endocrinol Metab. 2006.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.